TIRZEPATIDE · 60 MG | Control Potente del Apetito y Peso

Tirzepatide is the same active ingredient used in prescription medications such as Mounjaro® and Zepbound® . It is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, incretin hormones that regulate appetite, satiety, and glucose metabolism . Unlike traditional GLP-1 agonists that act on a single receptor, Tirzepatide simultaneously activates both signaling pathways, potentiating glycemic control, promoting greater weight loss, and improving metabolic dysfunction . The result is more efficient fat loss and a body composition with more muscle and less stored fat. The problem it solves: Appetite control is one of the greatest challenges for maintaining a sustained caloric deficit. Tirzepatide acts on the central mechanisms of hunger and satiety, facilitating dietary adherence and fat loss without the side effects of traditional stimulants.

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, the same active ingredient used in medications such as Mounjaro® and Zepbound®. Acts by regulating appetite, increasing satiety, and improving glucose metabolism to naturally reduce caloric intake. 2026 research has demonstrated that Tirzepatide activates brown adipose tissue, a type of fat specialized in "burning" calories, contributing to energy expenditure beyond intake reduction. Lab grade with purity ≥99% by HPLC-MS. Each vial contains 60 mg of Tirzepatide as sterile lyophilized powder, designed for in vitro and animal model scientific research. Manufactured under strict GMP standards, with complete batch traceability and Certificate of Analysis available. SKU: SKU-TIRZEPATIDE-60MG. CAS: 2023788-19-2. Store at 2-8°C in a dry place protected from light. WARNING: This product is not FDA-approved for off-label use and carries risks.

Primary Benefit: Appetite Reduction and Weight Control

At its core, Tirzepatide is designed to regulate appetite, increase satiety, and improve glucose metabolism to naturally reduce caloric intake . By activating GLP-1 and GIP receptors in the brain, it decreases caloric intake by acting on hunger centers, increasing feelings of fullness, and reducing cravings . Phase III clinical studies have demonstrated that Tirzepatide provides substantial and sustained weight loss in people with obesity or overweight. In the SURMOUNT-1 trial, after 176 weeks, mean body weight reduction was 12.3% with the 5 mg dose, 18.7% with the 10 mg dose, and 19.7% with the 15 mg dose, compared to 1.3% in the placebo group .

Secondary Benefits: Glycemic Control, Satiety, and Energy Expenditure

Tirzepatide's dual action on GIP and GLP-1 receptors offers additional benefits that directly impact metabolic health and body composition:

Glycemic Control and Metabolic Improvement: Tirzepatide improves glucose control by stimulating glucose-dependent insulin secretion and suppressing glucagon release . In the SURMOUNT-1 trial, only 1.3% of participants in the Tirzepatide groups received a diagnosis of type 2 diabetes, compared to 13.3% in the placebo group (HR: 0.07) . This effect was maintained even after 17 weeks off treatment, where 2.4% of Tirzepatide participants and 13.7% of placebo participants had developed type 2 diabetes .

Brown Adipose Tissue (BAT) Activation: Research presented at ENDO 2026 has demonstrated that Tirzepatide activates brown adipose tissue, a type of fat specialized in "burning" calories to produce heat . In the TABFAT trial, Tirzepatide increased PET/CT-detectable BAT activity from 41.2% to 64.7% of participants, while no changes were observed in the placebo group . This effect was independent of weight loss, suggesting that Tirzepatide modulates energy expenditure at the tissue level . Signs of conversion of white subcutaneous fat into more metabolically active "beige" fat were also observed .

Waist Circumference Reduction: In the SURMOUNT-5 trial, patients treated with Tirzepatide experienced a waist circumference reduction of 18.4 cm compared to 13 cm in the semaglutide (Wegovy) group .

Altered Taste Perception: Recent research suggests that incretin-based therapies may alter taste perception, particularly sensitivity to sweet and salty tastes, which could contribute to increased satiety and reduced cravings .

Tirzepatide is typically administered as a standalone agent for appetite control and weight loss. Its combination with an appropriate resistance training protocol, controlled nutrition, and moderate caloric deficit can potentiate and accelerate fat loss and body composition improvement effects. Combination with other agents affecting the incretin system is not recommended without proper supervision.
Intended exclusively for research in weight control.